Effect of myeloperoxidase modified LDL on bovine and human aortic endothelial cells

El Samad,Ghadir; Bazzi,Samer; Karam,Marc; Zouaoui Boudjeltia,Karim; Vanhamme,Luc; Daher,Jalil

doi:10.3892/etm.2019.8109

Effect of myeloperoxidase modified LDL on bovine and human aortic endothelial cells

Authors:
- Ghadir El Samad
- Samer Bazzi
- Marc Karam
- Karim Zouaoui Boudjeltia
- Luc Vanhamme
- Jalil Daher
View Affiliations

Affiliations: Department of Biology, Faculty of Sciences, University of Balamand, Tripoli 100, Lebanon, Laboratory of Experimental Medicine (ULB 222 Unit), CHU de Charleroi, A. Vésale Hospital, Université Libre de Bruxelles, Montigny‑le‑Tilleul 6110, Belgium, Laboratory of Molecular Biology of Inflammation, IBMM, Faculty of Sciences, Université Libre de Bruxelles, Gosselies 6041, Belgium
Published online on: October 17, 2019 https://doi.org/10.3892/etm.2019.8109
Pages: 4567-4574
Copyright: © El Samad et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cardiovascular disease associated with atherosclerosis is a leading cause of death worldwide. Atherosclerosis is primarily caused by the dysfunction of vascular endothelial cells and the subendothelial accumulation of oxidized forms of low‑density lipoproteins (LDL). Early observations have associated fibrin deposition with atheroma plaque formation, which has led to the proposition that a decrease in endothelial cell fibrinolysis may negatively influence atherogenesis. It has been recently demonstrated that myeloperoxidase modified LDL (MoxLDL) decreases endothelial cell profibrinolytic capacity in real‑time. The present study investigated the role of MoxLDL in endothelial cell dysfunction by determining the molecules that may be involved in decreasing the fibrinolysis of human aortic endothelial cells (HAEC). Accordingly, reverse transcription‑quantitative PCR was performed to screen for the differential expression of major genes that are implicated in the fibrinolytic process. In addition, the response of the latter cell type to MoxLDL was compared with bovine aortic endothelial (BAE) cells. Furthermore, the effect of the treatment on the generation of reactive oxygen species (ROS) was also determined. Although the current study did not demonstrate an association between MoxLDL treatment and a change in the expression of any major fibrinolytic factor in HAEC, a discrepancy between HAEC and BAE cells with respect to their response to modified LDL treatment was observed. The result have also demonstrated that MoxLDL does not increase ROS generation in HAEC as opposed to the other major type of modified LDL, cupper oxidized LDL (CuoxLDL) that was reported to exhibit a positive effect at this level. The present study provided important insight into the different effects of MoxLDL and CuoxLDL in endothelial cells, which may aid future studies to determine the various signaling pathways that are promoted by these molecules. The results of the present study may be utilized to identify potential molecular drug targets for the treatment of atherosclerosis.

View Figures

View References

1	Mathers CD and Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3:e4422006. View Article : Google Scholar : PubMed/NCBI
2	Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010. Lancet. 380:2095–2128. 2012. View Article : Google Scholar : PubMed/NCBI
3	Virchow R: Gesammelte Abhandlungen zur Wissenschaftlichen Medicin (Collected treatises on scientific medicine)Meidinger Sohn & Comp.; 1856
4	Galkina E and Ley K: Immune and inflammatory mechanisms of atherosclerosis (*). Ann Rev Immunol. 27:165–197. 2009. View Article : Google Scholar
5	Steinberg D, Parthasarathy S, Carew TE, Khoo JC and Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 320:915–924. 1989.PubMed/NCBI
6	Hansson GK: Regulation of immune mechanisms in atherosclerosis. Ann N Y Acad Sci. 947:157–166. 2001. View Article : Google Scholar : PubMed/NCBI
7	Daugherty A, Dunn JL, Rateri DL and Heinecke JW: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 94:437–444. 1994. View Article : Google Scholar : PubMed/NCBI
8	Delporte C, Boudjeltia KZ, Noyon C, Furtmuller PG, Nuyens V, Slomianny MC, Madhoun P, Desmet JM, Raynal P, Dufour D, et al: Impact of myeloperoxidase-LDL interactions on enzyme activity and subsequent posttranslational oxidative modifications of apoB-100. J Lipid Res. 55:747–757. 2014. View Article : Google Scholar : PubMed/NCBI
9	Hazell LJ, Baernthaler G and Stocker R: Correlation between intima-to-media ratio, apolipoprotein B-100, myeloperoxidase and hypochlorite-oxidized proteins in human atherosclerosis. Free Radic Biol Med. 31:1254–1262. 2001. View Article : Google Scholar : PubMed/NCBI
10	Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL and Hazen SL: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 286:2136–2142. 2001. View Article : Google Scholar : PubMed/NCBI
11	Wobst J, Kessler T, Dang TA, Erdmann J and Schunkert H: Role of sGC-dependent NO signalling and myocardial infarction risk. J Mol Med (Berl). 93:383–394. 2015. View Article : Google Scholar : PubMed/NCBI
12	Cesarman-Maus G and Hajjar KA: Molecular mechanisms of fibrinolysis. Br J Haematol. 129:307–321. 2005. View Article : Google Scholar : PubMed/NCBI
13	Delporte C, Van Antwerpen P, Vanhamme L, Roumeguere T and Zouaoui Boudjeltia K: Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies. Mediators Inflamm. 2013:9715792013. View Article : Google Scholar : PubMed/NCBI
14	Zouaoui Boudjeltia K, Daher J, Van Antwerpen P, Moguilevsky N, Delree P, Ducobu J, Raes M, Badran B, Vanhaeverbeek M, Brohee D, et al: Exposure of endothelial cells to physiological levels of myeloperoxidase-modified LDL delays pericellular fibrinolysis. PLoS One. 7:e388102012. View Article : Google Scholar : PubMed/NCBI
15	El Samad G: Effect of myeloperoxidase modified LDL on bovine and human aortic endothelial cells (unpublished PhD thesis)University of Balamand; El Koura: 2018
16	Colon S, Page-McCaw P and Bhave G: Role of hypohalous acids in basement membrane homeostasis. Antioxid Redox Signal. 27:839–854. 2017. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Eisenberg T, Carmona-Gutierrez D, Büttner S, Tavernarakis N and Madeo F: Necrosis in yeast. Apoptosis. 15:257–268. 2010. View Article : Google Scholar : PubMed/NCBI
19	Ocampo A and Barrientos A: Quick and reliable assessment of chronological life span in yeast cell populations by flow cytometry. Mech Ageing Dev. 132:315–323. 2011. View Article : Google Scholar : PubMed/NCBI
20	Deere D, Shen J, Vesey G, Bell P, Bissinger P and Veal D: Flow cytometry and cell sorting for yeast viability assessment and cell selection. Yeast. 14:147–160. 1998. View Article : Google Scholar : PubMed/NCBI
21	Chapin JC and Hajjar KA: Fibrinolysis and the control of blood coagulation. Blood Rev. 29:17–24. 2015. View Article : Google Scholar : PubMed/NCBI
22	Eruslanov E and Kusmartsev S: Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol. 594:57–72. 2010. View Article : Google Scholar : PubMed/NCBI
23	Barter P: Lipoprotein metabolism and CKD: Overview. Clin Exp Nephrol. 18:243–246. 2014. View Article : Google Scholar : PubMed/NCBI
24	Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW and Libby P: Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 158:879–891. 2001. View Article : Google Scholar : PubMed/NCBI
25	Steffen Y, Schewe T and Sies H: Epicatechin protects endothelial cells against oxidized LDL and maintains NO synthase. Biochem Biophys Res Commun. 331:1277–1283. 2005. View Article : Google Scholar : PubMed/NCBI
26	Daher J, Martin M, Rousseau A, Nuyens V, Fayyad-Kazan H, Van Antwerpen P, Courbebaisse G, Martiat P, Badran B, Dequiedt F, et al: Myeloperoxidase oxidized LDL interferes with endothelial cell motility through miR-22 and heme oxygenase 1 induction: Possible involvement in reendothelialization of vascular injuries. Mediators Inflamm. 2014:1346352014. View Article : Google Scholar : PubMed/NCBI
27	Chen XP, Xun KL, Wu Q, Zhang TT, Shi JS and Du GH: Oxidized low density lipoprotein receptor-1 mediates oxidized low density lipoprotein-induced apoptosis in human umbilical vein endothelial cells: Role of reactive oxygen species. Vascul Pharmacol. 47:1–9. 2007. View Article : Google Scholar : PubMed/NCBI
28	Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T and Masaki T: An endothelial receptor for oxidized low-density lipoprotein. Nature. 386:73–77. 1997. View Article : Google Scholar : PubMed/NCBI
29	Neri Serneri GG, Coppo M, Bandinelli M, Paoletti P, Toscano T, Micalizzi E, Chiostri M and Boddi M: Exaggerated myocardial oxLDL amount and LOX-1 receptor over-expression associated with coronary microvessel inflammation in unstable angina. Atherosclerosis. 226:476–482. 2013. View Article : Google Scholar : PubMed/NCBI
30	Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT and Boekholdt SM: Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: The EPIC-Norfolk prospective population study. J Am Coll Cardiol. 50:159–165. 2007. View Article : Google Scholar : PubMed/NCBI
31	Sueishi K, Ichikawa K, Kato K, Nakagawa K and Chen YX: Atherosclerosis: Coagulation and fibrinolysis. Semin Thromb Hemost. 24:255–260. 1998. View Article : Google Scholar : PubMed/NCBI
32	Qi J, Goralnick S and Kreutzer DL: Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells. Blood. 90:3595–3602. 1997. View Article : Google Scholar : PubMed/NCBI
33	Ahn K, Pan S, Beningo K and Hupe D: A permanent human cell line (EA.hy926) preserves the characteristics of endothelin converting enzyme from primary human umbilical vein endothelial cells. Life Sci. 56:2331–2341. 1995. View Article : Google Scholar : PubMed/NCBI
34	Koch M and Zernecke A: The hemostatic system as a regulator of inflammation in atherosclerosis. IUBMB Life. 66:735–744. 2014. View Article : Google Scholar : PubMed/NCBI
35	Romagnuolo R, Marcovina SM, Boffa MB and Koschinsky ML: Inhibition of plasminogen activation by apo(a): Role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). J Lipid Res. 55:625–634. 2014. View Article : Google Scholar : PubMed/NCBI
36	Aoyama T, Fujiwara H, Masaki T and Sawamura T: Induction of lectin-like oxidized LDL receptor by oxidized LDL and lysophosphatidylcholine in cultured endothelial cells. J Mol Cell Cardiol. 31:2101–2114. 1999. View Article : Google Scholar : PubMed/NCBI